DMG-ACT — Proving Global Scale and Feasibility

DMG-ACT (Diffuse Midline Glioma – Adaptive Combinatorial Therapy) is a global, multidisciplinary initiative transforming how children with DIPG and DMG are treated. Built on the belief that no single therapy will defeat these heterogeneous and aggressive tumors, DMG-ACT brings together world-leading clinicians, scientists, and institutions to rapidly identify, test, and advance the most promising treatment combinations for children battling these cancers.

By 2023, DMG-ACT demonstrated that a complex, adaptive platform trial could succeed on a global scale. Enrollment across PNOC022 accelerated rapidly, with patients enrolled at dozens of institutions across North America, Europe, Australia, and the Middle East. By August 2023, more than 130 children and young adults had enrolled, making PNOC022 the largest prospective DMG trial dataset ever assembled.

This scale enabled unprecedented collection of tumor tissue, blood, cerebrospinal fluid, microbiome samples, imaging, and patient-reported outcomes. ChadTough’s sustained support ensured consistency across sites and cohorts, allowing researchers to begin correlating biological features with treatment response and survival. In 2023, DMG-ACT proved not only that collaboration was possible—but that it could be executed at a level never before achieved in DIPG/DMG research.